Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments
Status:
Completed
Trial end date:
2018-03-30
Target enrollment:
Participant gender:
Summary
Hot flashes, vasomotor symptoms that affect many postmenopausal women, are associated with
cardiovascular disease and endothelial dysfunction. Estrogen therapy, associated or not with
progestogens, is the standard treatment for vasomotor symptoms and improves the endothelial
function of postmenopausal women with hot flushes, even those with cardiovascular risk
factors, such as hypertension. It is not known whether hot flushes are a cause for the
development of endothelial dysfunction or are markers of this dysfunction, evidenced by
estrogen deficiency, thus representing primitive target organ (vessel) lesion. Paroxetine was
approved by the FDA as a non hormonal treatment for menopausal hot flashes. In this
double-blind randomized clinical trial, the vascular effects of paroxetine at a dose of 7.5
mg / day, compared to placebo, during 12 weeks are evaluated.